期刊文献+

一阶导数紫外分光光度法测定氟脲嘧啶的血药浓度及动力学参数 被引量:2

The Research on Serum-concentration Pharmacokinetics of Fluorouracilum(5-Fu) by Derivative Spectrophotometry
暂未订购
导出
摘要 本实验选用一阶导数紫外分光光度法对氟脲嘧啶的血药浓度进行了测定,回收率为100.65%±1.77,CV 1.76%。揭示家兔体内氟脲嘧啶的药物动力学符合一室模型配置。其参数k=1.82±0.32h^(-1),t_(1/2)=0.39±0.07h,Vd=1.56±0.20L/kg。 This experiment is for the research on the pharmacokiretics of 5-Fu by deri-vative spectrophotmetry. When serum concentration of 5-Fu is tested by the mot-hod. The average recovery percent is 100. 56%±1.77 and CV is 1.76%. The pharma-cokinetics parameters have been determined by this method. And as a result,internal remedy is in conformity with the one-compartment, with parameterk=1. 82±0. 32h^(-1), T 1/2=0. 39±0. 07h Vd=1. 56±0. 20L/kg.
作者 何心
出处 《中国医院药学杂志》 CAS CSCD 北大核心 1991年第8期339-341,共3页 Chinese Journal of Hospital Pharmacy
关键词 氟脲嘧啶 分光光度法 血药浓度 Derivative Spectrophotometry Fluorouracilum serum concentration
  • 相关文献

同被引文献29

  • 1张红军.化疗药物对放射治疗的增效作用[J].国外医学(肿瘤学分册),1994,21(6):344-349. 被引量:4
  • 2赵斌,赵香兰.肿瘤病人的5—氟尿嘧啶药代动力学研究[J].癌症,1989,8(2):91-93. 被引量:10
  • 3胡璧.放射增敏药物研究的现状及其趋向[J].中华放射医学与防护杂志,1995,15(4):223-228. 被引量:3
  • 4张大昕,吴敏,高永君,王波,田长富,赵军.5-氟脲嘧啶、顺铂不同时相给药对放疗效果的影响[J].中国肿瘤临床,1997,24(4):285-287. 被引量:8
  • 5Yu H, Liu Y, Pan W, et al. Polyunsaturated fatty acids augment tumoricidal action of 5-fluorouracil on gastric cancer cells by their action on vascular endothelial growth factor, tumor necrosis factor-α and lipid metabolism related factors [ J]. Arch Med Sci, 2015, 11(2) : 282 -291.
  • 6Dilz L M, Denecke T, Steffen I G, et al. Streptozocin/5-fluorouracil chemotherapy is associated with durable response in patients with advanced pancreatic neureendocrine turnouts [ J ]. Eur J Cancer, 2015, 51(10) : 1253 -1262.
  • 7Matai I, Sachdev A, Gopinath P. Multicomponent 5-fluorouracil loaded PAMAM stabilized-silver nanocomposites synergistically induce apoptosis in human cancer cells [ J]. Biomater Sci, 2015, 3(3) : 457 -468.
  • 8Radwan A A, Alanasi F K. Design and synthesis of new cholesterol- conjugated 5-fluorouraeil: a novel potential delivery system for cancer treatment[J]. Molecules, 2014, 19(9) : 13177 -13187.
  • 9Longley D B, Harkin D P, Johnston P G. 5-fluorouraeil : mechanisms of action and clinical strategies [ J ]. Nat Rev Cancer, 2003, 3 ( 5 ) : 330 - 338.
  • 10Malet-Martino M, Martino R. Clinical studies of three oral prodrugs of 5-fluoreuracil (capeeitabine, UFT, S-I): a review[J]. Oneologist, 2002, 7(4) : 288 -323.

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部